Orphalan’s Cuvrior (trientine tetrahydrochloride) will join the US market five years after European Union approval, but with an indication for an earlier line of therapy for patients with Wilson’s disease, a rare inherited disorder of copper transport.
The FDA approved Cuvrior, a new salt of the copper chelating agent trientine, on 28 April 2022 for treatment of adult patients with stable Wilson’s disease who are de-coppered and...